Trans Genic Inc. (2342.T)
JPY 189.0
(2.72%)
JPY 189.0
(2.72%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -221.16 Million JPY | 78.77% |
| 2022 | -1.04 Billion JPY | 62.76% |
| 2021 | -2.79 Billion JPY | -170.5% |
| 2020 | -1.03 Billion JPY | -163.52% |
| 2019 | 1.62 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 437 Million JPY | 297.59% |
| 2023 Q1 | -710.53 Million JPY | 31.81% |
| 2023 Q4 | -221.16 Million JPY | -74.24% |
| 2023 Q3 | -126.93 Million JPY | 74.85% |
| 2023 Q2 | -504.64 Million JPY | 28.98% |
| 2023 FY | -221.16 Million JPY | 78.77% |
| 2022 Q4 | -1.04 Billion JPY | -25.09% |
| 2022 FY | -1.04 Billion JPY | 62.76% |
| 2022 Q3 | -833.02 Million JPY | 41.19% |
| 2022 Q2 | -1.41 Billion JPY | 0.0% |
| 2021 FY | -2.79 Billion JPY | -170.5% |
| 2020 FY | -1.03 Billion JPY | -163.52% |
| 2019 FY | -129.54 Million JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 129.777% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | 80.496% |
| GNI Group Ltd. | -17.93 Billion JPY | 98.767% |
| Linical Co., Ltd. | -4.46 Billion JPY | 95.045% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 94.967% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 95.383% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 115.428% |
| AnGes, Inc. | -3.79 Billion JPY | 94.176% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | 47.442% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 100.888% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | 55.602% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | 52.574% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 91.827% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 88.287% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | 77.481% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 93.489% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | 78.622% |
| Kidswell Bio Corporation | 343.58 Million JPY | 164.37% |
| PeptiDream Inc. | 3.29 Billion JPY | 106.718% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | 77.26% |
| Ribomic Inc. | -2.09 Billion JPY | 89.467% |
| SanBio Company Limited | -3.78 Billion JPY | 94.164% |
| Healios K.K. | -2.19 Billion JPY | 89.901% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | 76.592% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 91.572% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 84.392% |
| StemRIM | -8.41 Billion JPY | 97.37% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 95.278% |
| FunPep Company Limited | -1.79 Billion JPY | 87.667% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 89.648% |
| Stella Pharma Corporation | -1.11 Billion JPY | 80.242% |
| TMS Co., Ltd. | -3.44 Billion JPY | 93.583% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 96.019% |
| Cuorips Inc. | -5.56 Billion JPY | 96.023% |
| K Pharma,Inc. | -3.26 Billion JPY | 93.229% |
| Takara Bio Inc. | -32.2 Billion JPY | 99.313% |
| ReproCELL Incorporated | -2.93 Billion JPY | 92.475% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | 66.538% |
| StemCell Institute Inc. | -2.83 Billion JPY | 92.203% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 89.297% |
| CellSeed Inc. | -2.01 Billion JPY | 89.008% |